Category Archives: Generic drug

Hepatitis C drugs not reaching poor

Source: Nature 14 July 2014 Treatment guidelines for virus highlight challenge of paying for expensive drugs in low-income countries. The publication last week of the first treatment guidelines for hepatitis C virus (HCV), and the advent of drugs that can … Continue reading

Posted in Drug Pricing, Generic drug, IP Rights, patent | Leave a comment

More MSF patients with DR-TB gain access to dramatically cheaper version of life-saving drug

Patients & MSF doctors elated as MCC approval for MSF to use generic linezolid paves the way for national registration and access 02 July 2014 After a three-year long struggle, Médecins Sans Frontières (MSF) has received approval from the South African … Continue reading

Posted in Drug Pricing, Generic drug, Intellectual Property, patent | Leave a comment

Natco seeks to block Gilead’s hepatitis C drug patent in India: source

Source: Reuters 11 April 2014 (Reuters) – India’s Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc’s new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said. … Continue reading

Posted in Generic drug, Hepatitis - C, patent, Patent Opposition | Tagged , , | Leave a comment

Sun Pharma buys Ranbaxy to create generics giant

Source: Livemint 8 April 2014 Mumbai: Sun Pharmaceutical Industries Ltd, India’s biggest drug maker by market value, has agreed to acquire Ranbaxy Laboratories Ltd, controlled by Japan’s Daiichi Sankyo Co. Ltd, in an all-stock deal worth $3.2 billion that will … Continue reading

Posted in Generic drug, Other | Leave a comment

Joseph Stiglitz writes open letter to TPP negotiators

Source: KEI Professor Joseph Stiglitz has written an open letter to the TPP negotiators, asking that they resist proposals to weaken consumer rights in intellectual property. The letter identifies 12 specific “grave risks” in the IP Chapter, and calls upon … Continue reading

Posted in access to medicines, Biologics, Compulsory Licensing, Drug Pricing, Generic drug, IP Rights, IPR Enforcement, patent, patent evergreening, Right to Health, TPPA, Trans-Pacific Partnership Agreement, TRIPS, TRIPS plus, WHO, WTO | Tagged , | Leave a comment

Vietnam, other developing nations could lose as US seeks largesse for Big Pharma

Source: Thanhn Nien News Countries involved in negotiations for the Trans-Pacific Partnership face an aggressive American push for corporate-friendly trade rules that would force millions to pay more for drugs. Vietnamese, already squeezed by high drug prices, are likely to … Continue reading

Posted in access to medicines, Drug Pricing, Generic drug, Hepatitis - C, HIV/Aids, IP Rights, patent, patent evergreening, R&D, Right to Health, TB, TPPA, Trans-Pacific Partnership Agreement, TRIPS, USTR 301 report, World Health Assembly, WTO | Tagged , | Leave a comment

PLHIVs in Argentina file patent opposition against Gilead/BMS ARV combination Atripla

  Argentina, December 4 , 2013.- For the first time in Argentina organized communities filed a pre-grant opposition against a patent for a combination of antiretrovirals with priority use in the country. A pricing study conducted by RedLAM “Latin American … Continue reading

Posted in access to medicines, Compulsory Licensing, Drug Pricing, Generic drug, Hepatitis - C, HIV/Aids, IP Rights, IPR Enforcement, patent, patent evergreening, Patent examination system, Post grant opposition, TB | Tagged , , | Leave a comment